


Kif15-IN-2

Cat. No.:	HY-15949		
CAS No.:	672926-33-9		
Molecular Formula:	C ₂₀ H ₂₀ N ₆ O ₄ S		
Molecular Weight:	440.48		
Target:	Kinesin		
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 20 mg/mL (45.41 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
	Preparing Stock Solutions	1 mM	2.2703 mL	11.3513 mL
	5 mM	0.4541 mL	2.2703 mL	4.5405 mL
	10 mM	0.2270 mL	1.1351 mL	2.2703 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (4.54 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (4.54 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.
IC₅₀ & Target	KIF15
In Vitro	Kif15-IN-2 (Compound 14) is an inhibitor of the mitotic kinesin Hs Kif15, with the potential activities against cellular proliferative diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Quinazolinone derivatives useful for treating cellular proliferative disorders and disorders associated with Kif15 kinesin activity are described. US 20040053948 A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA